New hope for children: scisparc's patented cbd- enhanced solution for autism spectrum disorder

Tel aviv, israel, nov. 24, 2023 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare disease of the central nervous system, has initiated a clinical trial using its proprietary therapy, sci-210, at soroka medical center, israel, targeting autism spectrum disorder (asd) symptoms in children.
SPRC Ratings Summary
SPRC Quant Ranking